Man Group plc Increases Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Man Group plc grew its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 305.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 745,300 shares of the biotechnology company's stock after buying an additional 561,507 shares during the quarter. Man Group plc owned 0.32% of ADMA Biologics worth $12,782,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ADMA. Barclays PLC raised its holdings in ADMA Biologics by 192.2% during the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock worth $10,567,000 after purchasing an additional 347,692 shares in the last quarter. Perpetual Ltd acquired a new position in ADMA Biologics during the 4th quarter worth approximately $62,300,000. Nisa Investment Advisors LLC raised its stake in shares of ADMA Biologics by 133.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,378 shares of the biotechnology company's stock worth $127,000 after buying an additional 4,224 shares in the last quarter. Veracity Capital LLC lifted its holdings in shares of ADMA Biologics by 117.0% in the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after buying an additional 25,030 shares during the period. Finally, KBC Group NV lifted its holdings in shares of ADMA Biologics by 53.6% in the 4th quarter. KBC Group NV now owns 10,063 shares of the biotechnology company's stock valued at $173,000 after buying an additional 3,513 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA traded down $0.32 during trading hours on Wednesday, reaching $20.12. 2,405,413 shares of the company traded hands, compared to its average volume of 3,701,458. The stock has a market capitalization of $4.80 billion, a PE ratio of 71.86 and a beta of 0.57. The stock has a fifty day simple moving average of $20.61 and a 200 day simple moving average of $18.90. ADMA Biologics, Inc. has a fifty-two week low of $9.31 and a fifty-two week high of $25.67. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm's revenue was up 40.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.08 earnings per share. As a group, research analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of recent analyst reports. Raymond James upped their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. StockNews.com cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.